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Abstract
Backgrounds: We previously reported a highly sensitive method for serum human telomerase reverse transcriptase 
(hTERT) mRNA for hepatocellular carcinoma (HCC). α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) are good 
markers for HCC. In this study, we verified the significance of hTERTmRNA in a large scale multi-centered trial, collating 
quantified values with clinical course.
Methods: In 638 subjects including 303 patients with HCC, 89 with chronic hepatitis (CH), 45 with liver cirrhosis (LC) 
and 201 healthy individuals, we quantified serum hTERTmRNA using the real-time RT-PCR. We examined its sensitivity 
and specificity in HCC diagnosis, clinical significance, ROC curve analysis in comparison with other tumor markers, and 
its correlations with the clinical parameters using Pearson relative test and multivariate analyses. Furthermore, we 
performed a prospective and comparative study to observe the change of biomarkers, including hTERTmRNA in HCC 
patients receiving anti-cancer therapies.
Results: hTERTmRNA was demonstrated to be independently correlated with clinical parameters; tumor size and 
tumor differentiation (P < 0.001, each). The sensitivity/specificity of hTERTmRNA in HCC diagnosis showed 90.2%/85.4% 
for hTERT. hTERTmRNA proved to be superior to AFP, AFP-L3, and DCP in the diagnosis and underwent an indisputable 
change in response to therapy. The detection rate of small HCC by hTERTmRNA was superior to the other markers.
Conclusions: hTERTmRNA is superior to conventional tumor markers in the diagnosis and recurrence of HCC at an 
early stage.
Background
Since the discovery of circulating nucleic acids (CNAs) in
plasma in 1948, many diagnostic applications have
emerged. Recently, CNAs instead of a protein has
appeared on this scene of practical diagnostic assay, sug-
gesting that cell-free CNAs in the plasma/serum of can-
cer patients have characteristics of tumor-derived nucleic
acids. In addition to DNA-derived from tumor cells [1-4],
a recent development in this new field is the finding of
tumor-related RNA in the plasma/serum of cancer
patients [5]. These features include tyrosine kinase
mRNA [6], telomerase components [7,8], the mRNAs
that are encoded by different tumor-related genes [9-13],
and viral mRNA [14]. In one study, two telomerase mark-
ers in breast cancer yielded 44% of positive rates [7]. Nev-
ertheless, telomerase RNA seems to be a promising
marker by the reason that it can be found even in the
serum of patients with small, undifferentiated breast can-
cers without any metastatic lesions. Dasi et al. showed
that circulating telomerase RNA is a sensitive marker,
using real-time reverse transcription-PCR (RT-PCR) [8].
The telomerase catalytic subunit (hTERT) exerts
important cellular functions, including telomere homeo-
stasis, genetic stability, cell survival and perhaps differen-
tiation [15-20]. hTERTmRNA in serum was detected in
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breast cancer but not in benign diseases, suggesting that
hTERT is available for cancer diagnosis [4].
HCC ranks high among the most common and fatal
malignancies associated with hepatitis B virus (HBV) and
hepatitis C virus (HCV) infection [5]. Although HCC
patients receive possible medical treatments such as tran-
scatheter arterial chemoembolization/embolization
(TACE/TAE), radiofrequency ablation (RFA), and surgery
for primary tumors, intrahepatic and extrahepatic recur-
rence frequently limit patient's survival [6]. Although the
modalities such as ultrasonography (US) and conven-
tional tumor markers such as α-fetoprotein-L3 (AFP-L3)
and DCP are widely used and important for HCC detec-
tion in clinical scenes [7], they still do not provide an
entirely satisfactory solution to detect HCC at the early
stage. Since HCC has been recently classified as a com-
plex disease with a wide range of risk factors and many
c e l l u l a r  s i g n a l i n g  p a t h w a y s  h a v e  b e e n  r e p o r t e d  t o  b e
involved in hepatocarcinogenesis, a novel biomarker for
HCC is required [21]. We previously reported that mea-
surement of serum hTERTmRNA by real-time RT-PCR
method was sensitive in detection of tumor-derived
hTERTmRNA even in the HCC patients whose AFP lev-
els were low [9], and was also useful even for other malig-
nancies such as non-small cell lung cancer, ovarian
cancer, and gastric cancer [22-24]. In this large-scale
study that includes follow-up cases, we focused on HCC
of all malignancies and assessed the clinical significance
of hTERTmRNA measurement in HCC diagnosis and
monitored the clinical course.
Methods
Patients and Sample Collection
Four hundred-thirty seven consecutive patients (303
patients with HCC, 89 with CH, and 45 with LC), who
were admitted at Tottori University related Hospitals,
Osaka Red Cross Hospital, and Fukuoka University Chi-
kushi Hospital between November, 2002 and December,
2006, were enrolled in this study. All the HCC patients
had LC or CH as the underlying liver disease. The mean
ages of patients with HCC, LC, and CH were 65, 66, and
61 years, respectively. One hundred-sixty seven patients
were infected with HCV, 97 with HBV, 24 with both
viruses and 15 with no viral markers. The patients were
diagnosed by blood chemistry, US, computed tomogra-
phy (CT), AFP and/or biopsy under US. The clinico-
pathological findings (age, gender, etiology, underlying
liver disease (adjacent lesion), Pugh score, Child classifi-
cation, total bilirubin (TB), albumin (Alb), alanine amin-
otransferase (ALT), AFP , AFP-L3, DCP , HCV titer, HCV
subtype, tumor number, tumor size, differentiation
degree of tumor, and presence of metastasis) were evalu-
ated (Figure 1). HCC was diagnosed according to the
AASLD guidelines and the differentiation of HCC was
diagnosed by liver biopsy. Two hundred one healthy indi-
viduals including 144 females (from 24-87 years old:
mean age 57 years) served as controls. Informed consent
was obtained from each patient and the study protocols
followed the ethical guidelines of the 1975 Declaration of
Helsinki and were approved by the human research com-
mittee of Tottori University. The therapies for HCC
include TAE, transcatheter arterial infusion (TAI), percu-
taneus ethanol injection therapy (PEIT), and RFA.
Regarding follow-up patients, blood samples were taken
basically every two months.
RNA extraction and Real-time quantitative RT-PCR
Harvesting serum samples were performed as previously
described [9]. RNA was extracted with DNase treatment
from serum as reported previously [4,9]. The quantitative
RT-PCR was performed as described previously [5,10].
(a) for hTERT. The RT-PCR condition was an initial incu-
bation at 50 for 30 min followed by a 12-min incubation
at 95, then 50 cycles at 95 (0 s), 55 (10 s), and 72 (15 s),
and a 20 second melting at 40°C. The dynamic ranges of
real-time PCR analysis for hTERTmRNA were more than
approximately 5 copies in this assay and we were able to
exclude the possibility of false negativity in serum sam-
ples from patients with CH, LC and controls. The PCR
yielded products of 143 bp for hTERT (data not shown).
The RT-PCR assay was repeated twice and the quantifica-
tion was confirmed by using LightCycler (Roche, Basel,
Switzerland) with reproducibility.
hTERTmRNA during the treatment and detection of small 
HCC
We examined the therapeutic effectiveness of hTERT-
mRNA during the clinical course. Serum hTERTmRNA
was measured before and 7 days after TAE in 16 HCC
patients. In comparison with AFPmRNA, the half-life of
hTERTmRNA was examined. By monitoring gene expres-
sion in serum up to 6 months after the beginning of ther-
apy such as TAE, TAI, RFA, PEIT, surgical treatment, the
effect of therapies were estimated in 20 patients. Further-
more, we examined hTERTmRNA expression and level of
other conventional tumor markers after they were cate-
gorized by the tumor size (less than 10 mm, 11-20 mm,
21-30 mm, more than 30 mm).
Immunohistochemistry
For immunohistochemical analysis, of 303 patients, 50
HCC patients (24 patients with HCV, 9 with HBV, 10 with
both viruses, and 7 with unknown etiology; 5 patients
with well-, 3 with well~moderately-, 32 with moderately-,
3 with moderately~poorly-, and 7 with poorly-differenti-
ated HCC) with 35 positive and 15 negative conventional
tumor markers, who underwent surgical treatment, were
chosen. The immunohistochemical procedures were
done as reported previously [25]. The sections were incu-Miura et al. BMC Gastroenterology 2010, 10:46
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bated with the following monoclonal antibodies: anti-
hTERT (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), anti-Ki67 (Santa Cruz Biotechnology), anti-
TUNEL (Sigma Chemical, MO, USA), HBsAg (Sigma
Chemical), and HCV core antibody (Sigma Chemical).
Expression degree was confirmed and estimated of
hTERT, Ki-67, and TUNEL by the percentage of posi-
tively-stained cell number [26-28].
Statistical analysis
Multivariate analysis was performed using SPSS 13.0
(SPSS Corp., T okyo, Japan). Stratified categories in each
clinical parameter were evaluated by One Way ANOVA
and multivariate analysis using a logistic regression analy-
sis model. To assess the accuracy of the diagnostic tests,
the matched data sets (chronic liver diseases patients and
HCC patients) regarding AFP, AFP-L3, DCP, and hTERT-
mRNA were analyzed by using receiver operator charac-
teristic (ROC) curve analysis. The correlation of
hTERTmRNA between HCC tissue and serum was ana-
lyzed using both Paired t test and Spearman's test. The
detection rates of HCC in comparison with tumor size
were evaluated by Friedman test.
Results
RNA extraction and Real-time quantitative RT-PCR
In each quantitative assay, a strong linear relation was
demonstrated between copy number and PCR cycles
using RNA controls for concentration (r2 > 0.99; data not
shown). hTERTmRNA expression showed stepwise up-
regulation with disease progression and the quantifica-
tion was significantly higher in HCC than in LC, CH and
healthy individuals (P < 0.001, P < 0.01 and P < 0.001,
respectively, Figure 2A). ROC curve analyses showed that
the sensitivity/specificity of hTERTmRNA for HCC were
90.2%/85.4% (Figure 2B). Optimal cut-off values for
hTERTmRNA expressions were predicted as 9,332 cop-
ies/0.2 ml by stressing the higher specificity. Forty six
(15%) of HCC patients, whose AFP, AFP-L3, and DCP
were within normal limits, had 4.23 ± 0.32 logarithmic
values of hTERTmRNA, and 20 patients of 46 patients
were positive for this assay.
Multivariate analysis showed that hTERTmRNA was
associated with tumor size and differentiation degree of
tumor (P < 0.001, each, Figure 1 &3). However, hTERT-
mRNA was not associated with age, gender, etiology,
b a c k g r o u n d  l e s i o n  o r  n u m b e r  o f  t u m o r .  O n  t h e  o t h e r
hand, AFP was related to tumor size and differentiation
Figure 1 Multivariate analysis of tumor markers with clinical parameters in patients with HCC.Miura et al. BMC Gastroenterology 2010, 10:46
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(P = 0.008 and P = 0.0199), AFP-L3 was related to num-
ber of tumor and differentiation degree (P = 0.003 and P
= 0.001), and DCP was associated with only number of
tumor (P = 0.029). By Pearson relative test, serum
hTERTmRNA significantly associated with tumor size
and number of tumors (P < 0.033 and P < 0.003, respec-
tively, Table 1). Importantly, hTERTmRNA was related
only to DCP (P = 0.03).
ROC curve analyses showed that the sensitivity/speci-
ficity of hTERTmRNA for HCC were 90.2%/85.4% (Table
2). The sensitivity/specificity of AFP, AFP-L3, and DCP
were 76.6/66.2, 60.5/88.7, and 83.4/80.3, respectively.
Thus, hTERTmRNA was superior to other markers espe-
cially in sensitivity. The positive predictive value (PPV)/
negative predictive value (NPV) of hTERTmRNA were
83.0/85.9. On the other hand, the PPV/NPV for AFP,
AFP-L3, and DCP were 74.6/67.7, 59.6/92.2, and 78.4/
73.5, respectively. Consequently, hTERTmRNA was supe-
rior to other markers in the diagnosis of HCC. Combina-
tions of hTERTmRNA with AFP level improved the
sensitivity/specificity up to 96.0%/87.2%. ROC curve
analysis categorized by viruses was examined and sensi-
tivity/specificity in HBV-infected cases was similar to
that of HCV-infected cases (additional file 1). hTERT and
other markers in LC was not statistically and significantly
different in comparison with that in CH.
Estimation of therapeutic effect and the possibility of early 
HCC detection of hTERTmRNA in comparison with other 
biomarkers
To examine the significance of hTERTmRNA before and
after TAE, serum hTERTmRNA was measured before
and 7 days after TAE in 16 HCC patients (Figure 4A). As a
result, hTERTmRNA significantly decreased after TAE (P
= 0.018), suggesting that changes in hTERTmRNA are
indicative of therapeutic effects on HCC. Comparing the
follow-up data of hTERTmRNA and AFP (Figure 4B, C),
Figure 2 Serum hTERTmRNA and AFP mRNA expression in patients with HCC, LC, and CH, and in healthy individuals and receiver operator 
characteristics (ROC) curve analyses of hTERTmRNA, AFP, AFP-L3, and DCP. A. hTERTmRNA level in liver diseases. Serum hTERTmRNA levels and 
AFPmRNA level in patients with HCC, LC, CH, and healthy individuals by real-time RT-PCR were shown. The 95% confidence interval in each group is 
shown beside the dots. Significant differences between 4 groups are shown in the upper part of the figure. NL, individual with normal liver; CH, chronic 
hepatitis; LC, liver cirrhosis; HCC, hepatocellular carcinoma. Optimal cut-off values for hTERTmRNA expressions were predicted as 9,332 copies/0.2 ml. 
B. ROC curve analysis of hTERTmRNA, AFP, AFP-L3, and DCP was obtained by importing quantified raw data into SPSS II software. The data were ana-
lyzed by Paired t test (P = 0.01) and non-parametric Spearman's test (P = 0.017). AUC of each biomarker in ROC curve analysis is shown. Receiver op-
erator characteristic (ROC) curve analysis of hTERTmRNA, AFP, AFP-L3, and DCP was obtained by importing quantified raw data into SPSS II. The solid 
line, bold dotted line, dotted line, and bold solid line correspond to DCP, AFP, AFP-L3 and hTERTmRNA, respectively.Miura et al. BMC Gastroenterology 2010, 10:46
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the half-life of hTERTmRNA was shorter than that of
AFP.
To clarify the significance of hTERTmRNA in monitor-
ing the effect of therapies in comparison with other bio-
markers, two representative cases were depicted in Figure
5. The quantification of hTERTmRNA was performed
before, 2 and 5 months after RFA in a 73-year-old male
patient whose HCC was a single 21 mm-sized (Figure
5A). hTERTmRNA changed similar to AFP, AFP-L3, and
DCP, suggesting that hTERTmRNA is useful for monitor-
ing the clinical course of HCC. In a 78-year-old female
patient whose HCC was a single 38 mm-sized, a surgical
operation was performed (Figure 5B). The values of AFP,
DCP, and hTERTmRNA were measured before, 2 and 7
months after the operation. The operation was per-
formed successfully in this patient, however recurrence
was found by dynamic CT at 7 months after the opera-
tion. Although neither AFP nor DCP detected the recur-
rence, only hTERTmRNA did. In all the cases that hTERT
detected recurrence in the earlier stage, no other imaging
modality could detect it at the same time, but when we
could find HCC in images such as US, CT, or MR, other
markers began to arise.
Finally, we examined the relationship between the posi-
tive rates of biomarkers and tumor size. Positive rate of
hTERTmRNA was higher than that of the other markers
in each category of tumor size; 6-10 mm, 11-20 mm, 21-
30 mm, over 31 mm by Friedman test (P = 0.017) (Figure
3). However, the positivity of hTERTmRNA expression
tended to reduce slightly in tumors with diameters that
exceeded than 51 mm (5.2 ± 1.9 for 56 patients with 31-
50 mm of HCC, 5.0 ± 1.8 for 43 patients with HCC over
51 mm; mean ± S.D.) (additional file 2). Dot blot regard-
ing the correlation of hTERT mRNA quantification with
tumor differentiation is shown in additional file 3. In a 6
mm HCC case, no marker other than hTERTmRNA was
elevated and only abdominal US caught the evidence of
HCC (Figure 6(a) A, B).
Immunohistochemistry
Immunohistochemical analysis showed that Ki-67 posi-
tivity was observed in the nuclei of cancer cells (Figure
6(b) A). hTERT was observed in both the nuclei and cyto-
plasm of cancer cells (Figure 6(b) B). Some TUNEL-posi-
tive cells were present in cancerous lesions, however the
prevalence was low (Figure 6(b) C). hTERT expression
was significantly associated with the labeling index of Ki-
67 (P = 0.023). When the labeling indices of Ki-67, hTERT
and TUNEL were compared with the differentiation
degree of HCC, both hTERT and Ki-67 were higher in
poorly differentiated HCC than in well and moderately
differentiated HCC (Figure 6(b) D).
Figure 3 Levels of hTERTmRNA in regard to tumor size (6-10 mm, 11-20 mm, 21-30 mm, and over 31 mm).Miura et al. BMC Gastroenterology 2010, 10:46
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Discussion
Since HCC has been recently classified as a complex dis-
ease with a wide range of risk factors and many cellular
signaling pathways have been reported to be involved in
hepatocarcinogenesis, a novel biomarker for HCC is
required [21]. Since an epoch-making assay to detect
telomerase activity was established [11], telomerase has
been examined in many kinds of cancers, precancerous
lesions and normal tissues using the telomeric repeat
amplification protocol and investigated the correlation
with telomere length [29,30]. Notwithstanding that
telomerase was definitely an unprecedented candidate
tumor marker due to its specificity to cancer, it has clini-
cally remained inapplicable because telomerase expres-
Table 2: The sensitivity/specificity of each tumor marker for HCC was depicted.
Sensitivity Specificity OR PPV/NPV Cut-off point
hTERTmRNA 90.2 85.4 19.0 83.0/85.9 3. 97 (logarithmic 
copy number)
AFP 76.6 66.2 11.1 74.6/67.7 <10 (ng/ml)
AFP-L3 60.5 88.7 2.2 59.6/92.2 <10 (%)
DCP 83.4 80.3 7.6 78.4/73.5 <40 (mAU/ml)
The sensitivity/specificity values are 90.2%/85.4% for hTERTmRNA, 76.6%/66.2% for AFP, 60.5%/88.7% for AFP-L3, and 83.4%/80.3% for DCP. 
Regarding a diagnostic assessment in sensitivity and specificity, hTERTmRNA is identified as the most excellent tumor marker. OR: odds ratio, 
PPV: positive predictive value (%), NPV: negative predictive value (%).
Table 1: The sensitivity/specificity of each tumor marker for hepatocellular carcinoma and a statistic evaluation of 
hTERTmRNA level to clinical parameter were shown.
clinical parameter average ± S.E. Pearson test
P value
Multivariate analysis
P value
tumor size (mm) 21.2 ± 0.1 0.033 <0.001
(range: 6-90)
tumor number 1.8 ± 0.1 0.003 N.S.
tumor differentiation N.S. <0.001
AFP (ng/ml) 6146 ± 4554 N.S. N.S.
(n = 353)
AFP-L3 (%) 6.7 ± 1.0 N.S. N.S.
(n = 213)
DCP (mAU/ml) 18780 ± 1044 0.03 N.S.
n = 346)Miura et al. BMC Gastroenterology 2010, 10:46
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sion has not been detected stably in body fluid [12]. In
serum, the hTERTmRNA derived from cancer cells
seemed to be undetectable because it becomes instable
by RNase in blood. Since RNAs in serum are unexpect-
edly stable within 24 hrs after drawing blood due to parti-
cle-associated complex in structure [13,14], it has been
suggested that they can be generally detected even in
RNase-rich blood. Actually, hTERTmRNA can be
d e t e c t e d  i n  s e r u m  f r o m  b r e a s t  c a n c e r  p a t i e n t s  a n d  i t s
maximum sensitivity and specificity are at most 40% and
100%, respectively [4]. The sensitivity in patients with
HCC rose to 89.7% in the semi-quantitative assay, and
thus compared favorably with the previous findings in
which the sensitivity and specificity of AFPmRNA were
69% and 50% for HCC, respectively [31]. Besides, with
respect to HCC detection, AFPmRNA was superior to
AFP level used routinely in clinic [32]. Recently, in the
present study, we reported the sensitivity to detect the
nucleotides in blood in the process of RNA extraction,
including centrifugation steps less than 1500 × g to
remove cellular proteins in serum and a primer set that
can detect hTERTmRNA more efficiently than primers in
the previous reports (data not shown). We previously
reported that hTERT expression was very faint in the
Figure 4 The change of hTERTmRNA before and 7days after TAE. A. Follow-up of serum hTERTmRNA before, 4, 7, 30 and 90 days after TAE. B. Fol-
low-up of serum AFP before, 4, 7, 30 and 90 days after TAE.Miura et al. BMC Gastroenterology 2010, 10:46
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serum from normal individuals indicating that lympho-
cytes and circulating normal cells express very low levels
of hTERTmRNA [9]. Because hTERTmRNA in lympho-
cytes is very low, elevated hTERTmRNA levels in serum
may mean that hTERTmRNA is derived from cancer
cells. Since we could detect negligible amounts of lym-
phocyte markers after three steps of centrifugation of
blood samples, the RNA extraction procedure seemed to
remove lymphocytes effectively. In addition, normal or
damaged hepatocytes express negligible amounts of
hTERT [33,34]. Furthermore, we previously showed the
significant correlation of hTERTmRNA expression
between tumor tissue and serum [32]. These data suggest
that hTERTmRNA detected in serum is derived from
tumor cells.
Previously, we reported that qualitative analysis of
serum hTERTmRNA was superior to AFP for the purpose
of the early detection of HCC, because hTERTmRNA was
detectable in HCC patients with normal AFP levels [9].
AFP is being widely used as a reliable marker of HCC not
in earlier stage but in the advanced stage [35]. However,
in this study, neither AFP was able to distinguish HCC
from non-cancerous liver diseases, nor hTERTmRNA
was correlated with AFP level (P = 0.201), suggesting that
quantitative analysis of serum hTERTmRNA was much
more sensitive for HCC diagnosis even in the early stage.
Because the induction of the abdominal (enhanced-)US,
CT, and MRI into the clinical scene enabled us to detect
smaller-sized HCC [36], the sensitivity of AFP in the early
detection of HCC became less than 70%. Unlike AFP
level, AFPmRNA was significantly correlated with
hTERTmRNA (P < 0.001) and more sensitive than AFP. In
the present study, we measured AFP-L3, since AFP-L3
has been reported to be a more HCC-specific marker
than AFP [37]. Indeed, the level of AFP-L3 correlated sig-
nificantly with differentiation and number of HCC
although that of AFP was correlated with tumor size and
differentiation.
In the present study, of 303 HCC patients, 24 patients
were negative below the calculated cut-off value (9,332;
3.97 as logarithmic number) for serum hTERTmRNA.
Although the reason why hTERTmRNA was negative in
Figure 5 Conventional tumor markers and hTERTmRNA detection during clinical course with therapeutic modalities. A. Changes of AFP, AFP-
L3, DCP and hTERTmRNA in RFA-treated case (male, 73 years old), of which HCC was 21 mm-sized and single. B.Changes of AFP, DCP and hTERTmRNA 
in surgical operation-treated case (female, 78 years old), of which HCC was 38 mm-sized and single.Miura et al. BMC Gastroenterology 2010, 10:46
http://www.biomedcentral.com/1471-230X/10/46
Page 9 of 12
these patients is not clear, eleven of 24 hTERTmRNA-
negative HCC patients had decompensated liver cirrhosis
as the underlying disease. It has been reported that dec-
ompensated liver cirrhosis had higher levels of serum
TGF-β that promotes apoptosis of immortalized hepato-
cytes and, in these cases, elevated TGF-β may stimulate
apoptosis, resulting in reduction of hTERTmRNA
[34,38,39]. hTERT-negative cases had no other common
characteristics with age, gender, etiology, child classifica-
tion etc. than tumor size, ALT, and surrounding lesion. In
23 cases (95.8%), ALT was within 1.5 fold normal limits.
In 17 cases (70.8%), surrounding lesion was LC including
decompensated situation. Tumor size in 12 cases (50%)
was over 30 mm, reflecting on the biological features of
cancer itself, as referred in Norton-Simon models regard
tumor growth [40]. AFP and DCP were positive in 16
(66.7%) and 11 (45.8%) cases, respectively, suggesting that
combinative use of these markers contributes to improve
the diagnostic specificity.
Thus, hTERTmRNA is not only improved in both sensi-
tivity and specificity but has a close correlation with
tumor size and number in an early stage of HCC. Since
HCC repeatedly recurs polyclonally after any treatment
as a biological characteristic, the measurement of serum
hTERTmRNA makes it possible to recognize recurrence
or therapeutic effect in details as well as the usefulness for
one-point diagnosis. In this respect, we have to undergo
follow-up study after the treatment of HCC [24]. hTERT-
mRNA expression was closely associated with well to
moderate differentiation degree of HCC and was
enhanced with the proliferation. We should clarify that
serum hTERTmRNA can be detected by what alterations
of other molecules during the cancer progression [41-43].
In lower differentiated HCC, tumor cells are proliferating
and hTERTmRNA has a tendency to correlate with the
differentiation degree and an apoptotic event never
reflect on the serum detection of cancer cell-derived
mRNAs (Figure 6). Nakashio et al. previously reported
the significant correlation of HCC differentiation with
Figure 6 Early detection of small HCC by circulating hTERT mRNA and immunohistochemical analysis of HCC tissues. (a) Imaging diagnosis 
regarding case with 6 mm HCC. A. Ultrasonography and B. computed tomography of the smallest HCC detected by hTERTmRNA. The diameter of HCC 
was 6 mm. Left, ultrasonography; right, CT (b) Immunohistochemical analysis of HCC tissues. A. Ki-67 staining (×400), B. hTERT staining (×400), C. TUNEL 
(×400), D. Labeling indices of Ki-67, hTERT and TUNEL in regard to differential degree of HCC.Miura et al. BMC Gastroenterology 2010, 10:46
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telomerase expression [44]. The results in the present
study confirmed their findings. hTERTmRNA showed
more sensitivity and specificity compared with AFP-
mRNA in HCC patients. However, in liver diseases other
than HCC, hTERTmRNA was not correlated with AFP-
mRNA. The higher specificity of hTERTmRNA in HCC
may be related to fact that AFPmRNA is produced in
HCC cells and injured hepatocytes and hTERT is pro-
duced mainly in HCC cells. Furthermore, we could detect
serum hTERTmRNA expression even in HCC patients
with less than 10 mm moderate-differentiated tumor,
indicating that hTERT are upregulated during rapid pro-
liferation of tumor at the early phase of oncogenesis, de-
differentiation.
Waguri et al. proved that there exist circulating cancer
cells derived from original HCC tissues in blood and they
can detect hTERTmRNA in blood [45]. The present study
suggests that quantification of hTERTmRNAs in serum
has diagnostic implications for HCC. Unless apoptosis of
cancer cells contributes to the early detection of HCC
using serum mRNA, the essence may be immunoreac-
tions [46]. The development of micro vessels may be also
involved in the step [47]. We will evaluate the correlation
of prognosis with hTERTmRNA and the availability of
hTERTmRNA in other cancers by comparison of hTERT-
mRNA with other tumor markers [48], and will study its
usefulness for inflammatory diseases in which cellular
reactions are active [49]. This method depends on RNA
stability in each process of RNA purification, storage, and
quantification. In the light of its superior positivity to
other markers, the assay will be applied for clinical use in
the strict condition because it is required to keep the
serum RNA as it is in blood and avoid the degradation of
RNA quality. Now we are improving RNA stability and
PCR condition to better cost/benefit of this assay. In the
future, another large-scale study will be required to con-
firm our results for monitoring HCC and the feasibility
for its detection even on a primary care level.
Conclusions
In sum, our results support the suggestion that quantifi-
cation of circulating hTERTmRNA expression is clinically
useful for the early detection of HCC. Furthermore,
hTERTmRNA is superior to conventional tumor markers
in the diagnosis and recurrence of HCC at the early stage.
Additional material
Abbreviations
(h)TERT: (human) telomerase reverse transcriptase protein; HCC: hepatocellular
carcinoma; HCV: hepatitis C virus; HBV: hepatitis B virus; LC: liver cirrhosis; CH:
chronic hepatitis; AFP: α-fetoprotein; DCP: des-γ-carboxy prothrombin; ALT: ala-
nine aminotransferase; Alb: albumin; CNA: Circulating nucleic acids.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YO analyzed biomedical data and provided blood sample as main researcher in
Osaka Red Cross Hospital. MN analyzed biomedical data in Kinki University. MK
analyzed biomedical data and provided blood sample as main researcher in
Kinki University. KY analyzed biomedical data and provided blood sample in
San-in Labor Welfare Hospital. TK analyzed clinical data and the practical analy-
sis in San-in Labor Welfare Hospital. KO analyzed HCC imaging data and the
analysis in Saiseikai Gotsu General Hospital. YK was in charge for case study in
Saiseikai Gotsu General Hospital. SM analyzed biomedical data and provided
blood sample as main researcher in Saiseikai Gotsu General Hospital EN was in
charge for case study and biomedical analysis in Saiseikai Gotsu General Hospi-
tal. YH analyzed clinical and biomedical data as main researcher in Saiseikai
Gotsu General Hospital comprehensively. MK analyzed biomedical data and
provided blood sample as main researcher in Matsue City Hospital. SS analyzed
biomedical data and provided blood sample as main researcher in Fukuoka
University Chikushi Hospital. YH performed biomedical and clinical analysis in
surgical case in Tottori University. HK analyzed biomedical data and provided
blood sample as chief researcher in San-in Labor Welfare Hospital. JH provided
the environment to analyze the data comprehensively. All authors read and
approved the final manuscript.
Acknowledgements
This study was supported by a Grant-in-Aid (18390208) for scientific research 
from the Ministry of Education, Science, and Culture and the Foundation for 
the Promotion of Cancer Research in Japan. All the PCR primers were designed 
by INTEC Web and Genome Informatics, Corporation (Tokyo, Japan).
Author Details
1Division of Pharmacotherapeutics, Department of Pathophysiological and 
Therapeutic Science, Faculty of Medicine, Tottori University, 86 Nishicho, 
Yonago, Tottori 683-8503, Japan, 2Department of Gastroenterology, Osaka Red 
Cross Hospital, 5-30 Fudegasaki-cho, Tennouji-ku, Osaka, Osaka 543-8555, 
Japan, 3Department of gastroenterology, Kinki University, 3-4-1 Kowakae, 
Higashi-Osaka, Osaka 577-8502, Japan, 4Department of Gastroenterology, 
Matsue City Hospital, 32-1 Noshira-cho, Matsue, Shimane 690-8509, Japan, 
5Department of Internal Medicine, Shimaneken Saiseikai Gotsu General 
Hospital, 1551 Gotsu-cho, Gotsu, Shimane 695-8505, Japan, 6Division of Organ 
Pathology, Faculty of Medicine, Tottori University, Nishicho 86, Yonago, 683-
8503, Japan, 7Internal Medicine, San-in Labor Welfare Hospital, 1-8-1 
Kaikeshinden, Yonago, Tottori 683-0002, Japan, 8Department of 
Gastroenterology, Fukuoka University Chikushi Hospital, 1-1-1 Zokumyoin, 
Chikusino, Fukuoka 818-8502, Japan, 9Department of Pathobiological Science 
and Technology, School of Health Science, Faculty of Medicine, Tottori 
University, 86 Nishicho, Yonago, Tottori 683-8503, Japan and 10Division of 
Molecular and Genetic Medicine, Department of Genetic Medicine and 
Regenerative Therapeutics, Tottori University School of Medicine, 86 Nishicho, 
Yonago, Tottori 683-8503, Japan
References
1. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, 
Meyne J, Ratliff RL, Wu JR: A highly conserved repetitive DNA sequence, 
Additional file 1 TIF ROC curve analysis and AUC in measurement cat-
egorized by viruses. ROC curve analysis and AUC in measurement catego-
rized by viruses are demonstrated. Sensitivity/specificity of hTERTmRNA 
expression in HBV-infected cases is similar to that in HCV-infected cases.
Additional file 2 MS word Positivity of each marker for HCC. Positivity 
of each marker for HCC was shown, categorized by tumor size.
Additional file 3 TIF Dot blot regarding the correlation of hTERT-
mRNA quantification with tumor differentiation. Serum hTERTmRNA 
quantification in HCC patients (n = 101) diagnosed by liver biopsy was 
shown, categorized by tumor differentiation. The quantification in serum of 
HCC patients with well-/moderately-/poorly-/un-differentiation was 4.4 ± 
1.4/5.4 ± 2.0/6.3 ± 3.3/5.9 ± 1.8 (mean ± SD).
Received: 23 July 2009 Accepted: 18 May 2010 
Published: 18 May 2010
This article is available from: http://www.biomedcentral.com/1471-230X/10/46 © 2010 Miura et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Gastroenterology 2010, 10:46Miura et al. BMC Gastroenterology 2010, 10:46
http://www.biomedcentral.com/1471-230X/10/46
Page 11 of 12
(TTAGGG)n, present at the telomeres of human chromosomes.  Proc 
Natl Acad Sci USA 1988, 85:6622-6626.
2. Paradis V, Dargère D, Laurendeau I, Benoît G, Vidaud M, Jardin A, Bedossa 
P: Expression of the RNA component of human telomerase (hTR) in 
prostate cancer, prostatic intraepithelial neoplasia, and normal 
prostate tissue.  J Pathol 1999, 189:213-218.
3. Kopreski MS, Benko FA, Kwak LW, Gocke CD: Detection of tumor 
messenger RNA in the serum of patients with malignant melanoma.  
Clin Cancer Res 1999, 5:1961-1965.
4. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, 
Schaeffer P, Mulcahy HE, Meyer P, Stroun M, Anker P: Telomerase RNA as 
a detection marker in the serum of breast cancer patients.  Clin Cancer 
Res 2000, 6:3823-3826.
5. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in 
the United States.  N Engl J Med 1999, 340:745-750.
6. Shirabe K, Takenaka K, Taketomi A, Kawahara N, Yamamoto K, Shimada M, 
Sugimachi K: Postoperative hepatitis status as a significant risk factor 
for recurrence in cirrhotic patients with small hepatocellular 
carcinoma.  Cancer 1996, 15:1050-1055.
7. Dohmen K, Shirahama M, Onohara S, Miyamoto Y, Torii Y, Irie K, Ishibashi 
H: Differences in survival based on the type of follow-up for the 
detection of hepatocellular carcinoma: an analysis of 547 patients.  
Hepatol Res 2000, 18:110-121.
8. Miura N, Horikawa I, Nishimoto A, Ohmura H, Ito H, Hirohashi S, Shay JW, 
Oshimura M: Progressive telomere shortening and telomerase 
reactivation during hepatocellular carcinogenesis.  Cancer Genet 
Cytogenet 1997, 93:56-62.
9. Miura N, Shiota G, Nakagawa T, Maeda Y, Sano A, Marumoto A, Kishimoto 
Y, Murawaki Y, Hasegawa J: Sensitive detection of hTERTmRNA in the 
serum of patients with hepatocellular carcinoma.  Oncology 2003, 
64:430-434.
10. Mitas M, Mikhitarian K, Walters C, Baron PL, Elliott BM, Brothers TE, Robison 
JG, Metcalf JS, Palesch YY, Zhang Z, et al.: Quantitative real-time RT-PCR 
detection of breast cancer micrometastasis using a multigene marker 
panel.  Int J Cancer 2001, 93:162-171.
11. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello 
GM, Wright WE, Weinrich SL, Shay JW: Specific association of human 
telomerase activity with immortal cells and cancer.  Science 1994, 
266:2011-2015.
12. Tatsuma T, Goto S, Kitano S, Lin YC, Lee CM, Chen CL: Telomerase activity 
in peripheral blood for diagnosis of hepatoma.  J Gastroenterol Hepatol 
2000, 15:1064-1070.
13. Ng EK, Tsui NB, Lam NY, Chiu RW, Yu SC, Wong SC, Lo ES, Rainer TH, 
Johnson PJ, Lo YM: Presence of filterable and non filterable mRNA in the 
plasma of cancer patients and healthy individuals.  Clin Chem 2002, 
48:1212-1217.
14. Tsui NB, Ng EK, Lo YM: Stability of Endogeneous and added RNA in 
blood specimens, serum, and plasma.  Clin Chem 2002, 48:1647-1653.
15. Nørgaard R, Kassem M, Rattan SI: Heat shock-induced enhancement of 
osteoblastic differentiation of hTERT-immortalized mesenchymal stem 
cells.  Ann N Y Acad Sci 2006, 1067:443-447.
16. Zhang X, Soda Y, Takahashi K, Bai Y, Mitsuru A, Igura K, Satoh H, Yamaguchi 
S, Tani K, Tojo A, et al.: Successful immortalization of mesenchymal 
progenitor cells derived from human placenta and the differentiation 
abilities of immortalized cells.  Biochem Biophys Res Commun 2006, 
29:853-859.
17. Gabet AS, Accardi R, Bellopede A, Popp S, Boukamp P, Sylla BS, Londoño-
Vallejo JA, Tommasino M: Impairment of the telomere/telomerase 
system and genomic instability are associated with keratinocyte 
immortalization induced by the skin human papillomavirus type 38.  
FASEB J 2008, 22:622-632.
18. Gandellini P, Folini M, Bandiera R, De Cesare M, Binda M, Veronese S, 
Daidone MG, Zunino F, Zaffaroni N: Down-regulation of human 
telomerase reverse transcriptase through specific activation of RNAi 
pathway quickly results in cancer cell growth impairment.  Biochem 
Pharmacol 2007, 73:1703-1714.
19. Burnworth B, Arendt S, Muffler S, Steinkraus V, Bröcker EB, Birek C, 
Hartschuh W, Jauch A, Boukamp P: The multi-step process of human 
skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.  
Eur J Cell Biol 2007, 86:763-780.
20. Xu L, Blackburn EH: Human cancer cells harbor T-stumps, a distinct class 
of extremely short telomeres.  Mol Cell 2007, 26:315-327.
21. Aravalli RN, Steer CJ, Cressman ENK: Molecular mechanisms of 
hepatocellular carcinoma.  Hepatology 2008, 48:2047-2063.
22. Miura N, Nakamura H, Sato R, Tsukamoto T, Harada T, Takahashi S, Adachi 
Y, Shomori K, Sano A, Kishimoto Y, et al.: Clinical usefulness of serum 
telomerase reverse transcriptase (hTERT) mRNA and epidermal growth 
factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.  
Cancer Sci 2006, 97:1366-1373.
23. Miura N, Kanamori Y, Takahashi M, Sato R, Tsukamoto T, Takahashi S, 
Harada T, Sano A, Shomori K, Harada T, et al.: A diagnostic evaluation of 
serum human telomerase reverse transcriptase mRNA as a novel 
tumor marker for gynecologic malignancies.  Oncol Rep 2007, 
17:541-548.
24. Tani N, Ichikawa D, Ikoma D, Tomita H, Sai S, Ikoma H, Fujiwara H, Kikuchi S, 
Okamoto K, Ochiai T, et al.: Circulating cell-free mRNA in plasma as a 
tumor marker for patients with primary and recurrent gastric cancer.  
Anticancer Res 2007, 27:1207-1212.
25. Shomori K, Sakatani T, Goto A, Matsuura T, Kiyonari H, Ito H: Thymidine 
phosphorylase expression in human colorectal mucosa, adenoma and 
carcinoma: role of p53 expression.  Pathol Int 1999, 49:491-499.
26. Yeh TS, Chen TC, Chen MF: Dedifferentiation of human hepatocellular 
carcinoma up-regulates telomerase and Ki-67 expression.  Arch Surg 
2000, 135:1334-1339.
27. Tahara H, Yasui W, Tahara E, Fujimoto J, Ito K, Tamai K, Nakayama J, 
Ishikawa F, Tahara E, Ide T: Immuno-histochemical detection of human 
telomerase catalytic component, hTERT, in human colorectal tumor 
and non-tumor tissue sections.  Oncogene 1999, 18:1561-1567.
28. Takeba Y, Sekine S, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida 
Y, Nakano H, Asakura T, Ohtsubo T, et al.: Irinotecan-induced apoptosis is 
inhibited by increased P-glycoprotein expression and decreased p53 in 
human hepatocellular carcinoma cells.  Biol Pharm Bull 2007, 
30:1400-1406.
29. Nakashio R, Kitamoto M, Tahara H, Nakanishi T, Ide T, Kajiyama G: 
Significance of telomerase activity in the diagnosis of small 
differentiated hepatocellular carcinoma.  Int J Cancer 1997, 22:141-147.
30. Plentz RR, Park YN, Lechel A, Kim H, Nellessen F, Langkopf BH, Wilkens L, 
Destro A, Fiamengo B, Manns MP, et al.: Telomere shortening and 
inactivation of cell cycle checkpoints characterize human 
hepatocarcinogenesis.  Hepatology 2007, 45:968-976.
31. Wong Ih-N, Leung T, Ho S, Lau WY, Chan M, Johnson PJ: 
Semiquantification of circulating hepatocellular carcinoma cells by 
reverse transcriptase polymerase chain reaction.  Br J Cancer 1997, 
76:628-633.
32. Miura N, Maeda Y, Kanbe T, Yazama H, Takeda Y, Sato R, Tsukamoto T, Sato 
E, Marumoto A, Harada T, et al.: Serum human telomerase reverse 
transcriptase messenger RNA as a novel tumor marker for 
hepatocellular carcinoma.  Clin Cancer Res 2005, 1:3205-3209.
33. Onishi T, Nouso K, Higashi T, Toshikuni N, Nakatsukasa H, Kobayashi Y, 
Uemura M, Yumoto E, Fujiwara K, Sato S, et al.: Cellular distribution of 
telomerase reverse transcriptase in human hepatocellular carcinoma.  
J Gastroenterol Hepatol 2003, 18:1168-1174.
34. Wege H, Chui MS, Le HT, Strom SC, Zern MA: In vitro expansion of human 
hepatocytes is restricted by telomere-dependent replicative aging.  
Cell Transplant 2003, 12:897-906.
35. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC: High alpha-
fetoprotein level correlates with high stage, early recurrence and poor 
prognosis of hepatocellular carcinoma: significance of hepatitis virus 
infection, age, p53 and beta-catenin mutations.  Int J Cancer 2004, 
112:44-50.
36. Leoni S, Piscaglia F, Righini R, Bolondi L: Management of small 
hepatocellular carcinoma.  Acta Gastroenterol Belg 2006, 69:230-235.
37. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, Takasaki 
K, Nakano M: Clinicopathologic features of patients with hepatocellular 
carcinoma seropositive for a-fetoprotein-L3 and seronegative for des-
g-carboxyprothrombin in comparison with those seropositive for des-
g-carboxy prothrombin alone.  J Gastroenterol Hepatol 2002, 17:772-778.
38. Cavin LG, Romieu-Mourez R, Panta GR, Sun J, Factor VM, Thorgeirsson SS, 
Sonenshein GE, Arsura M: Inhibition of CK2 activity by TGF-beta 1 
promotes IkappaB-alpha protein stabilization and apoptosis of 
immortalized hepatocytes.  Hepatology 2003, 38:1540-1551.
39. Prade-Houdellier N, Frébet E, Demur C, Gautier EF, Delhommeau F, 
Bennaceur-Griscelli AL, Gaudin C, Martinel V, Laurent G, Mansat-De Mas V, 
et al.: Human telomerase is regulated by erythropoietin and Miura et al. BMC Gastroenterology 2010, 10:46
http://www.biomedcentral.com/1471-230X/10/46
Page 12 of 12
transforming growth factor-beta in human erythroid progenitor cells.  
Leukemia 2007, 21:2304-2310.
40. Heitjan DF: Generalized Norton-Simon models of tumour growth.  Stat 
Med 1991, 10:1075-1088.
41. Yu GR, Kim SH, Park SH, Cui XD, Xu DY, Yu HC, Cho BH, Yeom YI, Kim SS, 
Kim SB, et al.: Identification of molecular markers for the oncogenic 
differentiation of hepatocellular carcinoma.  Exp Mol Med 2007, 
31:641-652.
42. Swisher JF, Khatri U, Feldman GM: Annexin A2 is a soluble mediator of 
macrophage activation.  J Leukoc Biol 2007, 82:1174-1184.
43. Lin SY, Elledge SJ: Multiple tumor suppressor pathways negatively 
regulate telomerase.  Cell 2003, 27:881-889.
44. Takahashi S, Kitamoto M, Takaishi H, Aikata H, Kawakami Y, Nakanishi T, 
Shimamoto F, Tahara E, Tahara H, Ide T, et al.: Expression of telomerase 
component genes in hepatocellular carcinoma.  Eur J Cancer 2000, 
36:496-502.
45. Waguri N, Suda T, Nomoto M, Kawai H, Mita Y, Kuroiwa T, Igarashi M, 
Kobayashi M, Fukuhara Y, Aoyagi Y: Sensitive and specific detection of 
circulating cancer cells in patients with hepatocellular carcinoma; 
detection of human telomerase reverse transcriptase messenger RNA 
after immunomagnetic separation.  Clin Cancer Res 2003, 9:3004-3011.
46. Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H, 
Kuzushima K, Takiguchi M, Kaneko S: Cytotoxic T cell responses to 
human telomerase reverse transcriptase in patients with 
hepatocellular carcinoma.  Hepatology 2006, 43:1284-1294.
47. Piao YF, He M, Shi Y, Tang TY: Relationship between microvessel density 
and telomerase activity in hepatocellular carcinoma.  World J 
Gastroenterol 2004, 15:2147-2149.
48. Fujita Y, Fujikane T, Fujiuchi S, Nishigaki Y, Yamazaki Y, Nagase A, Shimizu 
T, Ohsaki Y, Kikuchi K: The diagnostic and prognostic relevance of 
human telomerase reverse transcriptase mRNA expression detected in 
situ in patients with non small cell lung carcinoma.  Cancer 2003, 
98:1008-1013.
49. Miura N, Kabashima H, Shimizu M, Sato R, Tsukamoto T, Harada T, 
Takahashi S, Endo R, Nakayama N, Takikawa Y, et al.: Clinical impact of 
serum transforming growth factor-alpha mRNA as a predictive 
biomarker for the prognosis of fulminant hepatitis.  Hepatol Int 2008, 
2:213-221.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-230X/10/46/prepub
doi: 10.1186/1471-230X-10-46
Cite this article as: Miura et al., A novel biomarker TERTmRNA is applicable 
for early detection of hepatoma BMC Gastroenterology 2010, 10:46